Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

363
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
363
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

391
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
391
Angina IV: Management01:26

Angina IV: Management

389
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
389
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

798
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
798
Angina V: Nursing Management01:20

Angina V: Nursing Management

475
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
475
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

564
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
564

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Percutaneous mechanical circulatory support: options and importance].

Der Internist·2014
Same author

The effects of over-expression of the FK506-binding protein FKBP12.6 on K(+) currents in adult rabbit ventricular myocytes.

Pflugers Archiv : European journal of physiology·2009
Same author

Mycobacterium pinnipedii: transmission from South American sea lion (Otaria byronia) to Bactrian camel (Camelus bactrianus bactrianus) and Malayan tapirs (Tapirus indicus).

Veterinary microbiology·2007
Same author

K201 modulates excitation-contraction coupling and spontaneous Ca2+ release in normal adult rabbit ventricular cardiomyocytes.

Cardiovascular research·2007
Same author

Over-expression of FK506-binding protein FKBP12.6 alters excitation-contraction coupling in adult rabbit cardiomyocytes.

The Journal of physiology·2004
Same author

Luminal salmonella endotoxin affects epithelial and mast cell function in the proximal colon of pigs.

Scandinavian journal of gastroenterology·2003
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Related Experiment Video

Updated: Mar 16, 2026

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.7K

[Coronary interventions : Current developments for improved long-term results].

T Seidler1

  • 1Klinik für Kardiologie und Pneumologie, Herzzentrum, Universitätsmedizin Göttingen, Georg-August-Universität, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland. tim.seidler@med.uni-goettingen.de.

Der Internist
|August 11, 2016
PubMed
Summary
This summary is machine-generated.

New drug-eluting stents (DES) are the standard in cardiology, offering superior efficacy and similar safety to bare metal stents (BMS). Current evidence suggests no remaining indications for BMS use in most patient scenarios.

Keywords:
Coronary artery diseaseDrug-eluting stentsPercutaneous coronary interventionPlatelet aggregation inhibitorsTomography, optical coherence

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K

Related Experiment Videos

Last Updated: Mar 16, 2026

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.7K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K

Area of Science:

  • Interventional Cardiology
  • Cardiovascular Devices

Background:

  • New generation drug-eluting stents (DES) are the established standard of care in interventional cardiology.
  • DES demonstrate comparable safety and superior efficacy to bare metal stents (BMS), even in high-bleeding-risk patients.
  • There are likely no remaining clinical indications favoring the use of BMS over DES.

Purpose of the Study:

  • To review the current evidence supporting the use of new generation DES.
  • To evaluate the advancements in DES technology and their impact on patient outcomes.
  • To discuss the role of bioresorbable scaffolds and antiplatelet therapy duration in optimizing cardiovascular interventions.

Main Methods:

  • Review of scientific literature and clinical trial data on DES and BMS.
  • Analysis of safety and efficacy outcomes in various patient populations.
  • Evaluation of emerging technologies like bioresorbable scaffolds and procedural optimization strategies.

Main Results:

  • New generation DES are superior to BMS in efficacy and comparable in safety across multiple scenarios.
  • Despite ongoing technological advancements, no new DES generation has proven superior to existing ones.
  • Current data on bioresorbable scaffolds (e.g., ABSORB III trial) show encouraging safety and efficacy, though long-term benefits are yet to be fully established.

Conclusions:

  • Drug-eluting stents (DES) have largely replaced bare metal stents (BMS) in interventional cardiology due to superior outcomes.
  • Further optimization of DES technology is ongoing, but significant superiority of newer variations over existing ones is not yet demonstrated.
  • Individualized patient management, including assessment of ischemic versus bleeding risk and antiplatelet therapy duration, is crucial for improving outcomes in DES procedures.